300015 爱尔眼科
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,196,1343.50%20,367,15716,109,94715,000,80911,912,410
减:营业总成本4,021,5103.21%15,113,23312,152,47810,986,8238,610,759
    其中:营业成本2,686,7591.92%10,021,9757,980,3897,211,8875,833,826
               财务费用61,94426.21%73,6286,655106,44490,352
               资产减值损失----(383,606)(95,464)(217,209)(362,814)
公允价值变动收益(3,078)-108.77%(79,423)(356,890)(448,391)(380,413)
投资收益1,823-46.37%46,52343,910141,116159,039
    其中:对联营企业和合营企业的投资收益------(3)(59)(90)
营业利润1,233,3946.93%4,947,9473,534,5003,493,9982,674,177
利润总额1,202,6076.15%4,551,0193,335,0563,147,7552,363,274
减:所得税费用230,193-0.90%895,023646,059677,852486,105
净利润972,4147.96%3,655,9962,688,9972,469,9031,877,169
减:非控股权益72,938-39.04%297,124164,766146,559153,363
股东净利润899,47615.16%3,358,8722,524,2312,323,3441,723,805

市场价值指针
每股收益 (元) *0.09815.50%0.3640.2790.3340.326
每股派息 (元) *----0.1500.1000.1200.148
每股净资产 (元) *2.110-13.52%2.0212.3232.0922.391
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容